Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?

Eur Urol. 2023 Jun;83(6):505-507. doi: 10.1016/j.eururo.2023.03.004. Epub 2023 Mar 24.

Authors

Clara Cerrato¹, Morgan Roupret², Maria Carmen Mir³

Affiliations

¹ Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
² GRC 5 Predictive Onco-Uro, Department of Urology, Sorbonne University, AP-HP, Pitié Salpétrière Hospital, Paris, France.
³ Department of Urology, Alzira University Hospital, Valencia, Spain. Electronic address: mirmare@yahoo.es.

PMID: 36967360
DOI: 10.1016/j.eururo.2023.03.004

No abstract available

Publication types

Editorial
Comment

MeSH terms

Administration, Intravesical
Antibiotics, Antineoplastic / therapeutic use
Humans
Hyperthermia, Induced* / methods
Mitomycin / therapeutic use
Non-Muscle Invasive Bladder Neoplasms*
Urinary Bladder Neoplasms* / drug therapy

Substances

Mitomycin
Antibiotics, Antineoplastic